|
|||||
|
|
||||||
Journal of Oncology Practice, Vol 3, No 2 (March), 2007: pp. 54-59 © 2007 American Society of Clinical Oncology. DOI: 10.1200/JOP.0722001
Self-Reported Cognitive Impairment in Patients With CancerJames P. Wilmot Cancer Center, University of Rochester, Rochester School of Medicine and Dentistry, Rochester, NY Address reprint requests to: Sadhna Kohli, PhD, University of Rochester Cancer Center, Cancer Control Program, 601 Elmwood Ave, Box 704, Rochester, NY 14642; Sadhna_kohli{at}urmc.rochester.edu Purpose: Cancer patients often report cognitive impairment, manifested as problems with concentration and memory, following cancer therapy. As part of a large multicenter survey of cancer patients undergoing treatment, we investigated the frequency and severity of self-reported problems with memory and concentration over time.
Methods: A total of 595 patients undergoing treatment for solid tumors self-rated problems with memory and concentration, using an 11-point Likert scale (0 = "not present" to 10 = "as bad as you can imagine") at baseline before treatment began (T1), at their worst during treatment (T2), and at 6 months following treatment (T3). Any symptom level Results: Concentration problems were reported by 48% of the 595 participants at T1 (5% severe), 67% at T2 (18% severe), and 58% (8% severe) at T3. Problems with memory were reported by 53% at T1 (4% severe), 67% (18% severe) at T2, and 68% (11% severe) at T3. The average frequency and severity of both symptoms in patients receiving chemotherapy, with or without radiation, increased significantly between T1 and T2 (P < .001). Both symptoms were less severe in patients receiving radiation alone at all three measurements than in either of the chemotherapy groups (all P values < .001). Symptoms at T3 were significantly higher than T1 for all groups (P < .001). Conclusion: A significant proportion of patients undergoing cancer therapy self-report problems with memory and concentration. Cognitive problems get worse during treatment and are still in evidence 6 months following the conclusion of treatments.
|
|
|||||||||||
|
Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1935-469X. Print ISSN: 1554-7477
|